2023
Role of colectomy in the management of appendiceal tumors: a retrospective cohort study
Marks V, Kerekes D, Butensky S, Ahuja N, Johnson C, Turaga K, Khan S. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. BMC Gastroenterology 2023, 23: 398. PMID: 37978348, PMCID: PMC10655451, DOI: 10.1186/s12876-023-03019-4.Peer-Reviewed Original ResearchConceptsGoblet cell adenocarcinomaNon-mucinous adenocarcinomaRight hemicolectomyStage 2 diseaseNeuroendocrine neoplasmsTumor typesAppendiceal tumorsMucinous adenocarcinomaAppendiceal goblet cell adenocarcinomaRole of colectomyNational Cancer DatabasePostoperative hospital stayRetrospective cohort studyRisk-adjusted analysisRange of histologiesDifferent tumor typesConclusionsMost patientsHospital stayUnplanned readmissionCohort studySurgical treatmentHistologic typeSurgical outcomesCell adenocarcinomaCancer Database
2018
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
Lee V, Wang J, Zahurak M, Gootjes E, Verheul H, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clinical Cancer Research 2018, 24: 6160-6167. PMID: 30097434, DOI: 10.1158/1078-0432.ccr-18-0421.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerNeutropenic feverMetastatic colorectal cancer patientsDurable partial responseMost common toxicitiesDose-escalation studyColorectal cancer patientsInjection site reactionsOngoing phase IIPhase I trialInitial disease progressionCycles of treatmentCommon toxicitiesDrain infectionEvaluable patientsStable diseaseColonic obstructionPartial responseI trialMulticenter trialColorectal cancerGastrointestinal cancerSite reactionsCancer patientsDisease progressionTrends in Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Journal Of Surgical Research 2018, 234: 240-248. PMID: 30527480, DOI: 10.1016/j.jss.2018.09.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedLogistic ModelsMaleMiddle AgedPatient SelectionPeritoneal NeoplasmsPostoperative ComplicationsRisk FactorsTreatment OutcomeConceptsCRS/HIPECHyperthermic intraperitoneal chemotherapyMedian operative timeLength of stayPostoperative morbidityCytoreductive surgeryOperative timeIntraperitoneal chemotherapySelect patientsClinical outcomesSurgeons National Surgical Quality Improvement Program databaseNational Surgical Quality Improvement Program databaseCommon primary tumor siteQuality Improvement Program databaseMultivariable logistic regression analysisLow preoperative hematocritImprovement Program databasePreoperative serum albuminCareful patient selectionPrimary tumor siteLogistic regression analysisPostoperative complicationsPostoperative deathsPreoperative hematocritPeritoneal carcinomatosis
2017
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiationCombination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research 2017, 23: 2691-2701. PMID: 27979916, PMCID: PMC5457329, DOI: 10.1158/1078-0432.ccr-16-1729.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerObjective response rateCombination epigenetic therapyEstrogen receptorEndocrine therapyPrimary endpointPartial responseMulticenter phase II studyEpigenetic therapyAdditional partial responsesHormone-resistant diseasePhase II studyTime of progressionBreast cancer modelClin Cancer ResHistone deacetylase inhibitorsImportant therapeutic targetPosttreatment biopsiesTNBC cohortII studyBreast cancerDNA methyltransferase inhibitorTherapeutic targetResponse rateCancer modelCombination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study
Azad NS, el-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study. Oncotarget 2017, 5: 35326-35338. PMID: 28186961, PMCID: PMC5471058, DOI: 10.18632/oncotarget.15108.Peer-Reviewed Original ResearchConceptsCombination epigenetic therapyMetastatic colorectal cancerRECIST responseCRC patientsMedian progression-free survivalCycles of therapySignificant clinical activityMetastatic CRC patientsProgression-free survivalSubset of patientsM2 days 1Serial tumor biopsiesMulti-institutional studyHistone deacetylase inhibitor entinostatEpigenetic therapyColorectal cell linesSubcutaneous azacitidinePrimary endpointPrior therapyLiver involvementOverall survivalTolerable therapySerial biopsiesColorectal cancerClinical activity
2016
Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection
Laurence G, Ahuja V, Bell T, Grim R, Ahuja N. Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection. The American Journal Of Surgery 2016, 214: 432-436. PMID: 28082009, DOI: 10.1016/j.amjsurg.2016.12.018.Peer-Reviewed Original ResearchConceptsMultivisceral resectionAdvanced colorectal cancerColorectal cancerCancer patientsYear survivalNon-metastatic colorectal cancerRadiation treatmentRecto-sigmoid cancerFive-year survivalSignificant associated morbidityKaplan-Meier analysisExtensive surgical proceduresGreatest survival advantageEligible patientsAssociated morbiditySelect patientsMeier analysisStandard surgeryRadical operationSEER dataAdjacent organsSurgical proceduresSurvival advantagePatientsSurgical specialists
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreasSurvival Following Lung Metastasectomy in Soft Tissue Sarcomas
Giuliano K, Sachs T, Montgomery E, Guzzetta A, Brock M, Pawlik TM, Yang SC, Ahuja N. Survival Following Lung Metastasectomy in Soft Tissue Sarcomas. The Thoracic And Cardiovascular Surgeon 2015, 64: 150-158. PMID: 26339728, DOI: 10.1055/s-0035-1563538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantKaplan-Meier EstimateLung NeoplasmsMaleMetastasectomyMiddle AgedNeoplasm GradingPneumonectomyRetrospective StudiesRisk FactorsSarcomaSoft Tissue NeoplasmsThoracoscopyTime FactorsTreatment OutcomeYoung AdultConceptsDisease-free intervalSoft tissue sarcomasLung metastasectomyTissue sarcomasLonger disease-free intervalLower pathologic gradeMedian overall survivalKaplan-Meier estimatesLog-rank testLow-grade tumorsGreatest survival advantageOverall survivalPostoperative factorsImproved survivalPatient selectionTumor characteristicsPathologic gradeMetastasis diagnosisCommon siteSurvival advantageSurvival analysisYounger ageMetastasectomyPatientsSurvival
2014
Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms
Lennon AM, Victor D, Zaheer A, Ostovaneh MR, Jeh J, Law JK, Rezaee N, Dal Molin M, Ahn YJ, Wu W, Khashab MA, Girotra M, Ahuja N, Makary MA, Weiss MJ, Hirose K, Goggins M, Hruban RH, Cameron A, Wolfgang CL, Singh VK, Gurakar A. Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. Liver Transplantation 2014, 20: 1462-1467. PMID: 25155689, PMCID: PMC4322915, DOI: 10.1002/lt.23983.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmHigh-risk featuresBranch-duct intraductal papillary mucinous neoplasmsLiver transplant patientsRisk of progressionBD-IPMNsPapillary mucinous neoplasmLT patientsLT recipientsTransplant patientsMucinous neoplasmsControl groupManagement of patientsHistory of immunosuppressionHigh-grade dysplasiaControl patientsSurgical resectionBD-IPMNConsecutive patientsExtrahepatic malignanciesMedian lengthMalignant potentialHigh riskPatientsSporadic patientsA comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample
Ejaz A, Sachs T, He J, Spolverato G, Hirose K, Ahuja N, Wolfgang CL, Makary MA, Weiss M, Pawlik TM. A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery 2014, 156: 538-547. PMID: 25017135, PMCID: PMC4316739, DOI: 10.1016/j.surg.2014.03.046.Peer-Reviewed Original ResearchConceptsMIS patientsInpatient outcomesLiver operationsNationwide Inpatient Sample databasePreoperative medical comorbiditiesIncidence of complicationsMultiple comorbid conditionsShorter median lengthAppropriate International ClassificationNationwide Inpatient SampleInvasive surgery techniquesDuration of stayHospital mortalityPostoperative morbidityHepatic resectionMedical comorbiditiesPancreatic resectionComorbid conditionsMIS groupMedian lengthOpen surgeryInpatient SampleOpen procedureRobotic assistInternational ClassificationClinicopathologic Presentation and Natural History of Anorectal Melanoma: A Case Series of 18 Patients
Hicks CW, Pappou EP, Magruder JT, Gazer B, Fang S, Wick EC, Gearhart SL, Ahuja N, Efron JE. Clinicopathologic Presentation and Natural History of Anorectal Melanoma: A Case Series of 18 Patients. JAMA Surgery 2014, 149: 608-611. PMID: 24848283, DOI: 10.1001/jamasurg.2013.4643.Peer-Reviewed Original ResearchConceptsAnorectal melanomaOverall disease-specific mortalityNatural historyDisease-specific mortalityDisease-specific survivalNonspecific presenting symptomsWide local excisionRare malignant neoplasmVariable natural historyNonspecific presentationPresenting symptomAbdominoperineal resectionLocal excisionCase seriesMedian timeSurgical managementRectal lesionsMalignant neoplasmsPrognostic parametersClinicopathologic presentationLate diagnosisAdvanced stageIncorrect diagnosisSmall lesionsLarger study
2013
2564 resected periampullary adenocarcinomas at a single institution: trends over three decades
He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. Hepato Pancreato Biliary 2013, 16: 83-90. PMID: 23472829, PMCID: PMC3892319, DOI: 10.1111/hpb.12078.Peer-Reviewed Original ResearchConceptsPeriampullary adenocarcinomaBile ductSingle institutionPancreatic cancerIntraductal papillary mucinous neoplasmNumber of patientsPapillary mucinous neoplasmRelative survival ratesCurative intentWorse survivalLongterm outcomesMucinous neoplasmsSafe resectionLongterm survivalPathological diagnosisPrimary siteSurvival ratePancreaticoduodenectomyAdenocarcinomaPatientsSurvivalResectionSignificant differencesCancerDiagnosis
2011
Predicting the Risk of Perioperative Mortality in Patients Undergoing Pancreaticoduodenectomy: A Novel Scoring System
Venkat R, Puhan MA, Schulick RD, Cameron JL, Eckhauser FE, Choti MA, Makary MA, Pawlik TM, Ahuja N, Edil BH, Wolfgang CL. Predicting the Risk of Perioperative Mortality in Patients Undergoing Pancreaticoduodenectomy: A Novel Scoring System. JAMA Surgery 2011, 146: 1277-1284. PMID: 22106320, DOI: 10.1001/archsurg.2011.294.Peer-Reviewed Original ResearchConceptsTotal pancreatectomyCharlson indexInstitutional databaseRisk scorePreoperative serum albumin levelHigher Charlson indexPreoperative risk factorsHigh-risk patientsSerum albumin levelTertiary referral centerMultivariate logistic regressionHosmer-Lemeshow testNovel scoring systemSimple integer scoreHigh-volume programPerioperative mortalityReferral centerAlbumin levelsMale sexTumor sizeTraining cohortRisk factorsTherapeutic decisionsObservational studyPancreatectomyGenomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer
Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N. Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research 2011, 17: 1535-1545. PMID: 21278247, PMCID: PMC3077819, DOI: 10.1158/1078-0432.ccr-10-2509.Peer-Reviewed Original ResearchConceptsDNA methylationExtracellular matrixDNA methylation analysisEpigenetic mechanismsKey genesEpigenomic alterationsCore pathwaysEpigenetic abnormalitiesPathway genesECM genesMultiple genesEpigenetic alterationsPathway componentsPathway analysisIntegrative analysisLarge CRC cohortsGenesMethylationMethylation analysisSimultaneous methylationPathway disruptionPathwayAggregate roleNovel prognostic biomarkerEVL
2009
Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series
Reddy S, Cameron JL, Scudiere J, Hruban RH, Fishman EK, Ahuja N, Pawlik TM, Edil BH, Schulick RD, Wolfgang CL. Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series. Journal Of The American College Of Surgeons 2009, 208: 950-957. PMID: 19476869, PMCID: PMC3109868, DOI: 10.1016/j.jamcollsurg.2009.01.044.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary neoplasmMalignant potentialFormal surgical resectionMedian tumor sizeOutcomes of patientsLymph node metastasisRare pancreatic tumorR1 resectionAbdominal painR0 resectionR2 resectionInstitutional seriesMost patientsSurgical resectionUnrelated causesClinicopathologic characteristicsComplete resectionMedian ageNode metastasisDistant metastasisPerineural invasionSurgical managementCommon symptomsLongterm outcomesTumor size
2008
Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers
Reddy S, Edil BH, Cameron JL, Pawlik TM, Herman JM, Gilson MM, Campbell KA, Schulick RD, Ahuja N, Wolfgang CL. Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers. Annals Of Surgical Oncology 2008, 15: 3199-3206. PMID: 18784960, DOI: 10.1245/s10434-008-0140-7.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaPancreatic resectionMetachronous lesionsMetastatic lesionsVascular invasionConclusionLong-term survivalResultsForty-nine patientsLymph node metastasisLangerhans cell histiocytosisDistal pancreatectomyPerioperative deathsPostoperative morbidityTotal pancreatectomyIsolated metastasisMedian survivalMetastatic diseaseSynchronous lesionsNode metastasisPrimary diseasePrimary cancerMedian lengthCell carcinomaGallbladder cancerSingle institutionCell histiocytosisIs There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?
Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? Annals Of Surgical Oncology 2008, 15: 2388. PMID: 18622647, PMCID: PMC3072702, DOI: 10.1245/s10434-008-0015-y.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerLeft-sided colon cancerProportional hazards regression analysisHazards regression analysisColon cancerMedian survivalCox proportional hazards regression analysisLongitudinal population-based databaseLong-term survival outcomesEnd Results Program databaseInvasive colon adenocarcinomaRight-sided cancersOverall median survivalLeft-sided cancersYear of diagnosisPopulation-based databaseRetrospective survival analysisSubset of subjectsRegression analysisSEER databaseSurgical resectionLymph nodesWorse prognosisSurvival outcomesTumor sizeConvergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis. PLOS Medicine 2008, 5: e114. PMID: 18507500, PMCID: PMC2429944, DOI: 10.1371/journal.pmed.0050114.Peer-Reviewed Original ResearchConceptsTumor suppressor geneUnbiased genome-wide approachSuppressor geneGenome-wide approachesKey tumor suppressor genesBreast cancer cell linesSet of genesCancer cell linesLarge-scale sequencingTumor suppressor statusPromoter CpG island hypermethylationCell linesCpG island hypermethylationTumor-type specificRecent sequencingBiology of cancerEpigenetic eventsCancer genomesEpigenetic analysisEpigenetic alterationsCommon genesTumor suppressorSignificant genesGenetic changesIsland hypermethylation
2005
Long‐Term Function After Restorative Proctocolectomy
Wheeler JM, Banerjee A, Ahuja N, Jewell DP, Mortensen NJ. Long‐Term Function After Restorative Proctocolectomy. Diseases Of The Colon & Rectum 2005, 48: 946-951. PMID: 15868242, DOI: 10.1007/s10350-004-0885-4.Peer-Reviewed Original ResearchConceptsIleoanal pouch surgeryLong-term functional outcomePercent of patientsFunctional outcomePouch surgeryRestorative proctocolectomyIleoanal pouchExcellent long-term optionEarly functional outcomesLong-term functionMost patientsPouch failureConsecutive patientsMedian agePerfect continencePatientsProctocolectomyStandardized questionnaireSurgeryOutcomesPouchMinimal dataMonthsTotalQuestionnaire